Observational studyJournal of medicine and life2026
COVID-19 severity and early inflammatory biomarkers in patients with immune-mediated inflammatory rheumatic diseases: a multicenter cohort study.
Observational study in Journal of medicine and life, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with immune-mediated inflammatory rheumatic diseases (IMIRDs) may be more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection because of underlying immune dysregulation. However, it remains unclear which factors determine coronavirus disease 2019 (COVID-19) severity in this population, especially in Eastern European settings. We conducted a retrospective, multicenter observational study including 211 patients with IMIRDs diagnosed with COVID-19 between 01.03.2020 and 31.12.2024. We collected clinical, demographic, and laboratory data within the first 72 hours of symptom onset and classified COVID-19 severity into three ordered categories. Associations with severity were examined using separate univariable ordinal logistic regression models and an additional multivariable model including age and IMIRD subtype. The main factors linked to more severe COVID-19 were older age (adjusted odds ratio [OR] 1.06; 95% confidence interval [CI]:1.03-1.09) and comorbidity burden (OR = 1.22; 95% CI, 1.12-1.31). Among patients with available laboratory measurements, higher levels of acute-phase reactants, as well as a higher derived neutrophil-to-lymphocyte ratio (dNLR) (OR = 1.30; 95% CI, 1.10-1.54) and lower monocyte counts (OR = 0.08; 95% CI, 0.02-0.36), remained associated with increased severity after Bonferroni correction for multiple comparisons. Accounting for age, patients with SLE had lower odds of greater COVID-19 severity than those with RA (OR = 0.35; 95% CI, 0.13-0.90). COVID-19 severity was associated with age, comorbidity burden, and early inflammatory response, with an age-adjusted difference also observed between SLE and RA. Routine inflammatory parameters and composite indices may contribute to early risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.